The 24 references in paper O. Shakhmatova O., Е. Panchenko P., О. Шахматова О., Е. Панченко П. (2018) “КАК СНИЗИТЬ РИСК КРОВОТЕЧЕНИЯ ПРИ ЧРЕСКОЖНЫХ КОРОНАРНЫХ ВМЕШАТЕЛЬСТВАХ У ПАЦИЕНТОВ С ФИБРИЛЛЯЦИЕЙ ПРЕДСЕРДИЙ: УРОКИ РАНДОМИЗИРОВАННЫХ ИССЛЕДОВАНИЙ И НОВЫЕ КЛИНИЧЕСКИЕ РЕКОМЕНДАЦИИ // HOW TO MINIMIZE THE BLEEDING RISK IN PATIENTS WITH ATRIAL FIBRILLATION UNDERGOING PERCUTANEOUS CORONARY INTERVENTIONS: LESSONS DRAWN FROM RANDOMIZED TRIALS AND NEW CLINICAL GUIDELINES” / spz:neicon:aterotromboz:y:2018:i:1:p:93-106

1
Rubboli A, Colletta M, Herzfeld J, Sangiorgio P, Di Pasquale G. Periprocedural and medium-term antithrombotic strategies in patients with an indication for long-term anticoagulation undergoing coronary angiography and intervention. Coron Artery Dis, 2007, 18: 193–199.
(check this in PDF content)
2
Wang T Y, Robinson LA, Ou FS et al. Discharge antithrombotic strategies among patients with acute coronary syndrome previously on warfarin anticoagulation: physician practice in the CRUSADE registry. Am Heart J, 2008, 155: 361–368.
(check this in PDF content)
3
Perez-Gomez F, Alegria E, Berjon J et al. Comparative effects of antiplatelet, anticoagulant, or combined therapy in patients with valvular and nonvalvular atrial fibrillation: a randomized multicenter study. J Am Coll Cardiol, 2004, 44: 1557–66.
(check this in PDF content)
4
Ruiz-Nodar JM, Marin F, Hurtado JA et al. Anticoagulant and antiplatelet therapy use in 426 patients with atrial fibrillation undergoing percutaneous coronary intervention and stent implantation implications for bleeding risk and prognosis. J Am Coll Cardiol, 2008, 51: 818–825.
(check this in PDF content)
5
Hansen ML, Sorensen R, Clausen MT et al. Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation. Arch Intern Med, 2010, 170: 1433–1441.
(check this in PDF content)
6
Lamberts M, Olesen JB, Ruwald MH et al. Bleeding after initiation of multiple antithrombotic drugs, including triple therapy, in atrial fibrillation patients following myocardial infarction and coronary intervention: a nationwide cohort study. Circulation, 2012, 126: 1185–1193.
(check this in PDF content)
7
Windecker S, Kolh P, Alfonso F et al. 2014 ESC / EACTS Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart J, 2014, 35: 2541–2619.
(check this in PDF content)
8
Wijns W, Kolh P, Danchin N et al. Guidelines on myocardial revascularization. Eur Heart J, 2010, 31: 2501–2555.
(check this in PDF content)
9
Connolly S, Pogue J, Hart R et al. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial Fibrillation Clopidogrel Trial With Irbesartan for Prevention of Vascular Events (ACTIVE W): a randomised controlled trial. Lancet, 2006, 367: 1903–1912.
(check this in PDF content)
10
Paikin JS, Wright DS, Crowther MA, Mehta SR, Eikelboom JW. Triple antithrombotic therapy in patients with atrial fibrillation and coronary artery stents. Circulation, 2010, 121: 2067–2070.
(check this in PDF content)
11
Dewilde WJM, Oirbans T, Verheugt FWA et al. Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an openlabel, randomised, controlled trial. Lancet, 2013, 381: 1107–1115.
(check this in PDF content)
12
Es RF, Jonker JJC, Verheugt FWA, Deckers JW, Grobbee DE, for the Antithrombotics in the Secondary Prevention of Events in Coronary Thrombosis-2 (ASPECT-2) Research Group. Aspirin and coumadin after acute coronary syndromes (the ASPECT-2 study): a randomised controlled trial. Lancet, 2002, 360: 109–113.
(check this in PDF content)
13
Hurlen M, Abdelnoor M, Smith P, Erikssen J, Arnesen H. Warfarin, aspirin, or both after myocardial infarction. N Engl J Med, 2002, 347: 969–974.
(check this in PDF content)
14
Fiedler KA, Maeng M, Mehilli J et al. Duration of triple therapy in patients requiring oral anticoagulation after drug-eluting stent implantation: the ISAR-TRIPLE trial. J Am Coll Cardiol, 2015, 65: 1619–1629.
(check this in PDF content)
15
Connolly SJ, Ezekowitz MD, Yusuf S et al. RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med, 2009, 361: 1139–1151.
(check this in PDF content)
16
Patel MR, Mahaffey KW, Garg J et al., for the ROCKET-AF Study Investigators. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med, 2011, 365: 883–891.
(check this in PDF content)
17
Granger CB, Alexander JH, McMurray JJ et al. ARISTOTLE Committees and Investigators. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med, 2011, 365: 981–992.
(check this in PDF content)
18
Giugliano RP, Ruff CT, Braunwald E et al., for the ENGAGE-AF-TIMI 48 Study Investigators. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med, 2013, 369: 2093–2104.
(check this in PDF content)
19
Kirchhof Р, Benussi S, Kotecha D et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. European Heart Journal, 2016, 37: 2893–2962.
(check this in PDF content)
20
Gibson CM, Mehran R, Bode C et al. Prevention of bleeding in patients with atrial fibrillation undergoing PCI. N Engl J Med, 2016, 375: 2423–2434.
(check this in PDF content)
21
Valgimigli М, Bueno Н, Byrne RA. et al. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS. European Heart Journal, 2017, 0: 1–48. doi:10.1093 / eurheartj / ehx419.
(check this in PDF content)
22
Cannon СР, Bhatt DL, Oldgren J et al. Dual Antithrombotic Therapy with Dabigatran after PCI in Atrial Fibrillation. N Engl J Med, 2017, 377: 1513–1524. doi: 10.1056 / NEJMoa1708454.
(check this in PDF content)
23
Hijazi Z, Oldgren J, Lindback J et al. The novel biomarker-based ABC (age, biomarkers, clinical history) – bleeding risk score for patients with atrial fibrillation: a derivation and validation study. Lancet, 2016, 387: 2302–2311.
(check this in PDF content)
24
Schomig A, Neumann FJ, Kastrati A et al. A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronaryartery stents. N Engl J Med, 1996, 334: 1084–1089.
(check this in PDF content)